Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025
Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xin, Si Waimei, Zhang Yuan, Yang Peiwen, Ruan Linjie, Ba He, Chen Zhen
Аннотация
PURPOSE: This study investigates the anti-tumor mechanisms of the natural triterpenoid Alpha-Heredin in pancreatic ductal adenocarcinoma, focusing on its dual effects on mitochondrial dynamics (via CAMKⅡ/DRP1 signaling) and ferroptosis induction.
METHODS: In vitro assays including CCK-8, EdU, colony formation, and flow cytometry were employed to assess Alpha-Heredin's effects on proliferation, migration, and cell cycle arrest. Functional studies utilized FerroOrange staining, MDA/GSH/SOD quantification, transmission electron microscopy (TEM), and MitoSOX/JC-1 assay to evaluate ferroptosis markers and mitochondrial function. Bioinformatics analysis integrated PDAC patient RNA-seq data (GSE85916) with GSVA and WGCNA to link mitochondrial dysfunction with ferroptosis pathways. Subcutaneous PDAC xenograft models treated with Alpha-Heredin (5/10 mg/kg) were analyzed for tumor growth, Ki-67/GPX4/xCT expression, and CAMKⅡ/DRP1 signaling in vivo.
KEY RESULTS: Alpha-Heredin dose-dependently suppressed PDAC proliferation and induced G0/G1 arrest. It inhibited CAMKⅡ/DRP1 phosphorylation, causing mitochondrial elongation, ROS accumulation, and cristae disruption. Ferroptosis induction was confirmed by iron overload, GSH/SOD depletion, and GPX4/xCT downregulation, reversible by Ferrostatin-1. In vivo, Alpha-Heredin (10 mg/kg) reduced tumor growth without systemic toxicity, while suppressing CAMKⅡ/DRP1 signaling and activating ferroptosis.
CONCLUSION: Alpha-Heredin suppresses PDAC progression by dual targeting of mitochondrial fission and ferroptosis activation, offering a novel therapeutic strategy against pancreatic cancer.
METHODS: In vitro assays including CCK-8, EdU, colony formation, and flow cytometry were employed to assess Alpha-Heredin's effects on proliferation, migration, and cell cycle arrest. Functional studies utilized FerroOrange staining, MDA/GSH/SOD quantification, transmission electron microscopy (TEM), and MitoSOX/JC-1 assay to evaluate ferroptosis markers and mitochondrial function. Bioinformatics analysis integrated PDAC patient RNA-seq data (GSE85916) with GSVA and WGCNA to link mitochondrial dysfunction with ferroptosis pathways. Subcutaneous PDAC xenograft models treated with Alpha-Heredin (5/10 mg/kg) were analyzed for tumor growth, Ki-67/GPX4/xCT expression, and CAMKⅡ/DRP1 signaling in vivo.
KEY RESULTS: Alpha-Heredin dose-dependently suppressed PDAC proliferation and induced G0/G1 arrest. It inhibited CAMKⅡ/DRP1 phosphorylation, causing mitochondrial elongation, ROS accumulation, and cristae disruption. Ferroptosis induction was confirmed by iron overload, GSH/SOD depletion, and GPX4/xCT downregulation, reversible by Ferrostatin-1. In vivo, Alpha-Heredin (10 mg/kg) reduced tumor growth without systemic toxicity, while suppressing CAMKⅡ/DRP1 signaling and activating ferroptosis.
CONCLUSION: Alpha-Heredin suppresses PDAC progression by dual targeting of mitochondrial fission and ferroptosis activation, offering a novel therapeutic strategy against pancreatic cancer.